Mounjaro for children and adolescents with type 2 diabetes: Anvisa approves and explains the indication

Anvisa approved this Wednesday the use of Mounjaro to treat type 2 diabetes in children and adolescents. The measure includes patients aged 10 to 17 years. Antes, the tirzepatide medication was only indicated for adults.
Essa extension makes Mounjaro the first in class of dual GIP and GLP-1 receptor agonists cleared for pediatric use in Brasil. The decision followed data evaluation from an international study. The change appears in the product leaflet after publication on Diário Oficial.
Aprovação published on April 22nd
Agência Nacional of Vigilância Sanitária formalized the expansion through Resolução-RE nº 1,592, of April 17, 2026. The text was published in Diário Oficial of União this Wednesday. The only change refers to the target population for type 2 diabetes. The other indications remain restricted to adults.
Brasil manufacturer Lilly reported that the approval was based on results from the SURPASS-PEDS trial. The phase 3 study involved young people with inadequate disease control even when using other treatments. Tirzepatide acted as a double agonist, unlike options that work only with GLP-1.
- The medicine is administered by weekly injection.
- Prescription is restricted to doctors.
- Use is combined with a balanced diet and physical activity.
- The indication is limited to cases of type 2 diabetes with insufficient response to previous therapies.
Medicamento acts on two intestinal hormones
Tirzepatide stimulates GIP and GLP-1 receptors. Essa dual action helps regulate insulin release, reduce glucose production in the liver and delay gastric emptying. The result includes better control of blood sugar levels.
Além In addition, the medicine influences appetite and metabolism. Estudos in adults already showed weight reduction. In the pediatric group, a similar effect on body mass index was observed. The mechanism represents an advance in relation to older treatments.

Clinical Estudo recorded a 2.2% drop in glycated hemoglobin
The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of tirzepatide in young people aged 10 to 17 years. Após 30 weeks, the group that received the drug had an average reduction of 2.2 percentage points in glycated hemoglobin. The placebo registered a small increase of 0.05%.
With the 10 mg dose, 86.1% of participants achieved glycated hemoglobin of 6.5% or less. Essa brand is considered an important target for disease control. The reduction in body mass index reached 11.2% with the highest dose in the same range. The gains were maintained when the study was extended to 52 weeks.
The safety profile was similar to that observed in adults. The most reported adverse events were nausea, vomiting and diarrhea. The majority had mild or moderate intensity. Não signs of new or unexpected problems have emerged in this age group.
Diabetes type 2 advances among young Brazilians
Brasil records significant growth in cases of type 2 diabetes in children and adolescents. Estima It is estimated that 213 thousand adolescents live with the disease. Outros 1.46 million have pre-diabetes. One in three cases of diabetes diagnosed at this age is type 2.
Pesquisa with more than 37 thousand students aged 12 to 17 showed a prevalence of 3.3% for type 2 diabetes and 22% for pre-diabetes. The same survey identified 8.4% with obesity and 20% with metabolic syndrome. Esses numbers indicate that the problem may still be underreported in the country.
Fatores as excess weight, sedentary lifestyle and inadequate diet drive the condition. Brasil occupies a high position in the global ranking of diabetes cases. The modern lifestyle contributes to the early onset of the chronic condition.
Multidisciplinary Abordagem gains importance
Especialistas advocate treatment that goes beyond medication. Mudanças in the lifestyle continue as a basis. Atividade Regular physical and balanced diet help control blood sugar and weight. Monitoring includes a nutritionist, physical educator and, when necessary, a psychologist.
Quality of life should guide decisions. Type 2 diabetes requires ongoing management. The medicine does not replace healthy habits. Ele is an option when other measures are not enough to achieve the desired control.
Uso off-label for weight loss requires caution
Mounjaro has gained visibility as a weight loss aid in adults. In the pediatric population, the leaflet only authorizes the treatment of type 2 diabetes. Use for obesity without diabetes does not have robust evidence of safety and efficacy at this age.
Profissionais warn of potential risks. Impactos in growth, puberty, eating behavior and mental health require monitoring. Distúrbios of body image may arise in teenagers. The balance between benefits and risks needs rigorous individual assessment.
Não There is enough data to recommend the medicine for aesthetic purposes in young people without a diagnosis of diabetes. Prescribing outside the approved indication is the responsibility of the doctor. The focus must remain on chronic disease management.
Perspectivas for disease management
The expansion of the indication opens up a new therapeutic option. Jovens with poorly controlled type 2 diabetes gain additional tool. The country faces increasing challenge with metabolic condition. Maior arsenal can contribute to better long-term results.
Individualized treatment remains essential. Cada patient presents different history and response. The doctor evaluates other medications being used, comorbidities and glycemic goals. Regular monitoring includes blood tests and checking for side effects.
Sociedade Brasileira of Diabetes and Sociedade Brasileira of Endocrinologia and Metabologia follow the theme. Updated Diretrizes incorporates new evidence. The objective is to reduce complications such as cardiovascular, kidney and neurological problems that diabetes can cause over the years.
Regulatory Avanço reflects scientific data
Anvisa’s decision followed a detailed analysis of the dossier submitted by the manufacturer. The SURPASS-PEDS study met efficacy and safety requirements for the pediatric population. Publication in the journal The Lancet in September 2025 reinforced the robustness of the findings.
Outros countries also evaluate tirzepatide for use in young people. No Brasil, approval represents alignment with recent evidence. The regulatory process prioritized protecting the health of the pediatric population. The updated leaflet guides professionals on dosage, contraindications and precautions.
Monitoramento continues after release
Anvisa maintains post-approval surveillance. Qualquer serious adverse event must be reported. Fabricantes and healthcare professionals participate in this system. The objective is to detect possible signs of risk not observed in clinical trials.
Pacientes and families receive clear guidance on warning signs. Persistent Náuseas, severe vomiting, or other symptoms require immediate contact with a physician. Treatment starts with a low dose and adjusts according to tolerance and response.
Type 2 diabetes requires daily commitment. The medicine is part of a larger strategy that includes health education. Escolas, families and public services can act in prevention. Redução of a sedentary lifestyle and promoting healthy eating help to contain the progression of the disease.






